In lung cancer, SMARCA4 inactivation affects about one-third of non-small cell lung cancers (NSCLCs) and preferentially occurs against a background of wild type MYC (either C, L or N) or of members of the MYC-axis, such as MAX or MGA4–7. This evidence concerns the gene MYC and non-small cell lung carcinoma.